Lucretinib, as an innovative JAK inhibitor, has shown significant efficacy in the treatment of diseases such as bone marrow fibrosis.

1、 Drug name

1. Common name: Ruxolitinib

2. Product Name: Jakafi ™

2、 Indications

Used for the treatment of patients with medium to high-risk bone marrow fibrosis, including primary bone marrow fibrosis, post polycythemia vera bone marrow fibrosis, and post thrombocytopenia bone marrow fibrosis.

3、 Specifications and characteristics

5mg tablets.

4、 Main components

1. Active ingredient: Lucatinib phosphate.

2. Accessories: Microcrystalline cellulose, lactose monohydrate, magnesium stearate, colloidal silica, hydroxypropyl cellulose, etc.

5、 Usage and dosage

1. Initial dose: adjusted according to platelet count:

Platelets>200 × 10 ⁹/L: 20mg twice daily.

Platelets 100-200 × 10 ⁹/L: 15mg twice daily.

2. Dose adjustment:

Monitor blood routine every 2-4 weeks and adjust the dosage according to the degree of thrombocytopenia (pause if platelet count<50 × 10 ⁹/L).

When the therapeutic effect is insufficient, it can be increased by 5mg every 2 weeks, with a maximum of 25mg twice a day.

3. Course of treatment: If there is no reduction in spleen size or improvement in symptoms within 6 months, the medication should be discontinued.

6、 Medication precautions

1. Diet: Can be taken with food or on an empty stomach.

2. Missed dose: Skip the missed dose and take the next dose according to the original plan.

3. Vomiting: If vomiting occurs after taking medication, there is no need to take additional medication.

4. Nasogastric tube administration: Dissolve the tablet in 40mL of water and stir for 10 minutes. Administer through the nasogastric tube within 6 hours, then rinse the tube with 75mL of water.

7、 Medication for special populations

1. Renal insufficiency:

Moderate or severe (CrCl15-59mL/min): Initial dose 10mg twice daily.

Patients with end-stage renal disease (CrCl<15mL/min) who do not require dialysis are contraindicated.

2. Liver dysfunction:

Any degree of liver dysfunction and platelet count of 100-150 × 10 ⁹/L: initial dose of 10mg twice daily.

Platelets<100 × 10 ⁹/L are contraindicated.

3. Pregnant and lactating women: Use only during pregnancy when the benefits outweigh the risks; Medication or breastfeeding should be stopped during lactation.

8、 Adverse reactions

1. Common hematological reactions: thrombocytopenia (69.7%), anemia (96.1%), and neutropenia (18.7%).

2. Non hematological reactions: bruising (23.2%), dizziness (18.1%), headache (14.8%), weight gain (7.1%).

3. Risk of infection: Be alert to opportunistic infections such as herpes zoster.

9、 Contraindications

Do not use it if there are no clear contraindications, but for severe liver and kidney dysfunction with platelet count<100 × 10 ⁹/L.

10、 Drug interactions

1. Strong CYP3A4 inhibitors (such as ketoconazole): should be reduced to 10mg twice daily.

2. Strong CYP3A4 inducers (such as rifampicin): may reduce efficacy and need to be monitored for efficacy.

11、 Storage method

Store at room temperature (20 ° C-25 ° C), avoiding moisture and light.

Ruxolitinibinformation